After Pirfenidone: Broad Competition To Bring First Therapy For Underlying Cause Of IPF To Market
Executive Summary
In the latest in “The Pink Sheet”’s market snapshot series, InterMune continues to work on getting pirfenidone approved in the U.S., while several companies are developing next-stage therapies for IPF.
You may also be interested in...
ASCEND Data Put InterMune’s Pirfenidone On Top
Phase III trial of idiopathic pulmonary fibrosis drug puts company in strong position for FDA approval of first treatment for orphan disease and strong reimbursement in U.S. and abroad.
ASCEND Data Puts InterMune’s Pirfenidone On Top
Phase III trial of idiopathic pulmonary fibrosis drug puts company in strong position for FDA approval of first treatment for orphan disease and strong reimbursement in U.S. and abroad.
Financings Of The Fortnight: Too Soon To Size Up Impact Of The U.S. JOBS Act
Plus news on recent financings by Onyx Therapeutics, InterMune, Versartis and Aileron Therapeutics.